BioAlliance Pharma Receives Market Approval for Loramyc(R) in the United Kingdom and Denmark.PARIS Paris, in Greek mythology Paris or Alexander, in Greek mythology, son of Priam and Hecuba and brother of Hector. Because it was prophesied that he would cause the destruction of Troy, Paris was abandoned on Mt. -- Regulatory News: BioAlliance Pharma SA (Paris: BIO) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member State) that it has just received the Marketing Authorisation for Loramyc[R] in the UK and Denmark. The grant of the Marketing Authorisation in the UK represents an important milestone for BioAlliance Pharma especially with the payment of EU2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc[R] in Europe. "We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teams and experts. Currently being launched in France, Loramyc[R] will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorisation for Loramyc[R] in the very near future", stated Dominique Costantini Chief Executive Officer. About BioAlliance Pharma BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections Opportunistic infections Infections that cause a disease only when the host's immune system is impaired. The classic opportunistic infection never leads to disease in the normal host. in cancer and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc[R]) in France and the compound is currently in Phase III clinical development in oropharyngeal oropharyngeal /oro·pha·ryn·ge·al/ (-fah-rin´je-al) 1. pertaining to the mouth and pharynx. 2. pertaining to the oropharynx. candidiasis candidiasis (kăn'dĭdī`əsĭs), infection of the mucous membranes caused by the fungus Candida albicans. Other terms for candidiasis are yeast infection, moniliasis (after a former name of the fungal genus), and thrush, the in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir acyclovir /acy·clo·vir/ (a-si´klo-ver) a synthetic purine nucleoside with selective activity against herpes simplex virus; used as the base or the sodium salt in the treatment of genital and mucocutaneous herpesvirus infections. Lauriad[R] in oral herpes (based on the same Lauriad[R] muco-adhesive technology as Loramyc[R], which enables targeted release at the disease site) and doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased Transdrug[R] in primary liver cancer Liver Cancer Definition Liver cancer is a relatively rare form of cancer but has a high mortality rate. Liver cancers can be classified into two types. (based on the Transdrug[R] nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and HIV markets. In 2007, the company has established strategic alliances for commercializing Loramyc[R] in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical). For more information, visit www.bioalliancepharma.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque ris·qué adj. Suggestive of or bordering on indelicacy or impropriety. [French, from past participle of risquer, to risk, from risque, risk; see risk.] Adj. ") section of the reference document approved by the AMF AMF ACE (Allied Command, Europe) Mobile Force AMF Autorité des Marchés Financiers (French) AMF Action Message Format AMF Arab Monetary Fund AMF Asian Monetary Fund AMF Autocrine Motility Factor on April 6(th) 2007 under the number R. 07-031, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com). For press releases and other company information, visit www.bioalliancepharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion